Ken Song was Appointed as President and Chief Executive Officer at Metacrine

Date of management change: September 15, 2016 

What Happened?

San Diego, CA-based Metacrine Appointed Ken Song as President and Chief Executive Officer

 

About the Company

We are a clinical-stage biopharmaceutical company focused on discovering and developing best-in-class therapies for patients with liver and gastrointestinal, or GI, diseases. Since our founding in 2014, we have invested in building a foundation of chemistry and biology expertise to drive innovative drug discovery and development. We believe these internal capabilities allow us to gain insights into disease targets and mechanisms and more quickly and purposefully design therapies with characteristics that we view as key to safety and efficacy. With this systematic approach, we have designed novel, proprietary farnesoid X receptor (FXR) clinical product candidates arising from a unique chemical scaffold with the potential to be best-in-class for non-alcoholic steatohepatitis, or NASH, and first- in-class for Inflammatory Bowel Disease, or IBD. In addition to our FXR program, we have continued to invest in drug discovery on other therapeutic targets that have effects on inflammation and/or fibrosis for which we believe we could develop proprietary small molecule therapies.

 

About the Person

Ken Song is President and Chief Executive Officer at Metacrine. Previously, Ken held various senior HR leadership roles in the industry.

 

Info Source

News

 
 

Other IT executives who recently changed jobs as well: Fish Jeff, Boshko Eileen, Dixon Michael, Murphy Tony, Epstein David, Thompson Joel, Blumberg Sheryl, Wagner Jim, Sachse Cindy, Price Jessica, Perino Lisa

You can find the full directory of IT executives here.

How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.